HER2/NEU NEGATIVE
Clinical trials for HER2/NEU NEGATIVE explained in plain language.
Never miss a new study
Get alerted when new HER2/NEU NEGATIVE trials appear
Sign up with your email to follow new studies for HER2/NEU NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for seniors with breast cancer: safer combo therapy shows promise
Disease control CompletedThis study looked at how well older adults (70+) with advanced, hormone-positive breast cancer tolerate a combination of palbociclib plus either letrozole or fulvestrant. The goal was to understand side effects and find factors that might predict who handles treatment better. 93 …
Matched conditions: HER2/NEU NEGATIVE
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 05:57 UTC
-
New drug combo offers hope for elderly breast cancer patients avoiding surgery
Disease control CompletedThis study tested a combination of two hormone-based drugs (fulvestrant and palbociclib) in 14 older patients with hormone-sensitive breast cancer who could not have surgery or chose not to. The goal was to control the cancer and avoid the need for surgery. The treatment aims to …
Matched conditions: HER2/NEU NEGATIVE
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:55 UTC
-
New combo therapy targets tough cancers in early trial
Disease control CompletedThis early-phase study tested a new drug (ALRN-6924) combined with standard chemotherapy (paclitaxel) in 28 adults with advanced solid tumors that had spread or couldn't be removed surgically, including a type of breast cancer. The main goal was to find the safest dose and check …
Matched conditions: HER2/NEU NEGATIVE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New hope for Hard-to-Treat breast cancer: drug combo shows promise
Disease control CompletedThis study tested a drug called alisertib, either alone or combined with the hormone therapy fulvestrant, in 96 postmenopausal women with advanced breast cancer that had stopped responding to standard hormone treatments. The goal was to see if these treatments could shrink tumors…
Matched conditions: HER2/NEU NEGATIVE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 18, 2026 12:00 UTC